Michael Holinstat

Dr. Michael Holinstat is a world-renowned expert in platelet physiology and pharmacology, with more than 70 peer-reviewed publications in the field. Dr. Holinstat’s laboratory at the University of Michigan focuses on understanding the complex signaling mechanisms which regulate hemostasis and thrombosis, and identifying novel approaches to anti-thrombotic therapy. Importantly, he is co-inventor of Veralox’s clinical product candidate. Dr. Holinstat leadership roles at the University of Michigan include 1) director for the MS degree in clinical research, 2) director for the Platelet Physiology and Pharmacology Core, and 3) therapeutic champion for the Fast Forward Medical Innovations commercialization program. Dr. Holinstat is a recipient of the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from the American Heart Association for his work on 12-lipoxygenase in cardiovascular medicine and is an elected fellow of the American Heart Association. Dr. Holinstat received his PhD in Pharmacology from the University of Illinois at Chicago and postdoctoral training at Vanderbilt University. He currently serves on numerous external boards including: 1) grant review boards for the US National Institutes of Health (NIH), French National Research Agency (ANR), UK Medical Research Council (MRC), 2) journal reviewer for Nature, JCI, Blood, and ATVB, and 3) serves on the editorial board for Frontiers in Pharmacology and Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).